Law360, New York (April 20, 2009, 12:00 AM ET) -- The U.S. Supreme Court on Monday declined to hear Gilead Sciences Inc.'s appeal of a finding that shareholders in a securities fraud class action against the drugmaker sufficiently alleged a causal relationship between the increase in sales from Gilead’s forbidden off-label marketing of its HIV drug Viread — artificially inflating the drug’s value for a time — and a later drop in the company's stock price.
In appealing an August decision by the U.S. Court of Appeals for the Ninth Circuit reversing the dismissal of the...
High Court Snubs Gilead's Loss Causation Appeal
To view the full article, take a free trial now.
